|
DC Treatment
|
TLR specificity
|
No Vaccine S.I.
|
Plus Vaccine S.I.
|
|---|
|
None
| |
-
|
-
|
|
+ LPS
|
4
|
4.1
|
4.0
|
|
+ Pam3CSK4
|
2
|
3.0
|
5.6
|
|
+ Flagellin
|
5
|
2.4
|
4.8
|
|
+ MALP-2
|
2, 6
|
3.0
|
5.6
|
|
+ Poly IC
|
3
| | |
|
(Fig. 2a-2b)
| |
3.6
|
6.0
|
|
Fig. 2c
| |
2.4
|
3.8
|
|
+ Loxoribine
|
7
|
1.25
|
4.0
|
|
+ R-848
|
7, 8
|
2.39
|
1.85
|
|
(Fig. 2c)
| | | |
|
+ Poly IC + R-848
|
3, 7, 8
|
NT
|
1.95
|
|
(Fig. 2c)
| | | |
- NT-not tested; Stimulation indices derived from allogeneicT cell responses in a standard 5-day 3H-TdR incorporation assay. Two donors were tested in Figure 2a & 2b and three donors were tested in Figure 2c.
